Page 43 - Boxed Warning News Today

/PRNewswire/ -- Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipelineScott Habig, as Chief Commercial Officer, to lead and enhance Aurinia’s commercial capabilities, replacing Max Colao, who led the formation of the...

The FDA has approved the sNDA for Zulresso to include patients 15 years of age and older with postpartum depression.

ProvayBlue injection is now available in a new 10mL single-dose vial for the treatment of patients with acquired methemoglobinemia.

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and...

/PRNewswire/ -- American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® (methylene blue) Injection, USP in...

The FDA has approved Breyanzi (lisocabtagene maraleucel) for adults with relapsed or refractory large B-cell lymphoma after 1 prior therapy.

The FDA has approved Breyanzi (lisocabtagene maraleucel) for adults with relapsed or refractory large B-cell lymphoma after 1 prior therapy.

The FDA has approved the sNDA for Zulresso to include patients 15 years of age and older with postpartum depression.